Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies

Trends in Immunology

Volumn 26, Issue 6, 2005, Pages 295-297

  Good, Michael F ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; RTS S VACCINE; SPOROZOITE VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DNA MODIFICATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; KNOCKOUT GENE; LIFE CYCLE; LIVER; MALARIA; NONHUMAN; PARASITE DEVELOPMENT; PARASITE IMMUNITY; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; RODENT; SHORT SURVEY; SPOROZOITE; VACCINE PRODUCTION;

ANIMALS; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM; SPOROZOITES;

EID: 19544374476     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2005.04.005     Document Type: Short Survey

References (23)

1. D. Kemp Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans Proc. Natl. Acad. Sci. U. S. A. 80 1983 3787 3791
2. J. Ellis Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi Nature 302 1983 536 538
3. S.L. Hoffman Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites J. Infect. Dis. 185 2002 1155 1164
4. Z. Su Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice Infect. Immun. 71 2003 5178 5187
5. T.C. Luke, and S.L. Hoffman Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine J. Exp. Biol. 206 2003 3803 3808
6. M.F. Good Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research Annu. Rev. Immunol. 23 2005 69 99
7. A.K. Mueller Genetically modified Plasmodium parasites as a protective experimental malaria vaccine Nature 433 2005 164 167
8. K. Matuschewski Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage J. Biol. Chem. 277 2002 41948 41953
9. A.K. Mueller Plasmodium liver stage development arrest by depletion of a protein at the parasite-host interface Proc. Natl. Acad. Sci. U. S. A. 102 2005 3022 3027
10. + T cells and antibodies required for immunity to malaria sporozoites Nature 330 1987 664 666
11. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites Proc. Natl. Acad. Sci. U. S. A. 85 1988 573 576
12. L.F. Scheller, and A.F. Azad Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites Proc. Natl. Acad. Sci. U. S. A. 92 1995 4066 4068
13. S.L. Hoffman Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications Science 237 1987 639 642
14. Y. Zevering Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax Proc. Natl. Acad. Sci. U. S. A. 91 1994 6118 6122
15. C. Ocana-Morgner Malaria blood stage suppression of liver stage immunity by dendritic cells J. Exp. Med. 197 2003 143 151
16. P.L. Alonso Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial Lancet 364 2004 1411 1420
17. + type 1 responses in humans by a malaria DNA vaccine Proc. Natl. Acad. Sci. U. S. A. 98 2001 10817 10822
18. D.L. Doolan, and S.L. Hoffman Nucleic acid vaccines against malaria Chem. Immunol. 80 2002 308 321
19. D. Tao Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model J. Exp. Med. 201 2005 201 209
20. + T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein J. Immunol. 172 2004 5561 5569
21. S.J. McConkey Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans Nat. Med. 9 2003 729 735
22. V.S. Moorthy A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults PLoS Med. 1 2004 e33
23. M.F. Good Towards a blood stage vaccine for malaria. Are we following all the leads? Nat. Rev. Immunol. 1 2001 117 125